Study of heart disease caused by BAG3 gene changes
Part of Genetic & congenital, Heart & circulation clinical trials.
This study follows people with a specific genetic change (in the BAG3 gene) that causes heart muscle weakness, to learn more about how the condition progresses over time. It does not test a new drug, but it helps researchers understand the disease better, which may lead to future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed change (variant) in the BAG3 gene that is known to cause heart problems
- You have been diagnosed with dilated cardiomyopathy (a weakened, enlarged heart muscle) that is not caused by blockages in your heart arteries
- Your heart failure symptoms are mild to moderate (not severe)
- You have not had a heart transplant or gene therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
This trial tests an experimental gene therapy (AFTX-201) designed to address the genetic cause of heart failure in people with a specific BAG3 gene mutation. It aims to improve heart function and reduce symptoms.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This study offers genetic testing to adults with a type of heart muscle disease (non-ischemic cardiomyopathy or dilated cardiomyopathy) that is not caused by blocked arteries. The goal is to find genetic causes, which may guide treatment and family screening.
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.